{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:24:58Z","timestamp":1791599098944,"version":"4.3.4"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>To assess whether intravenous immunoglobulin (IVIG) followed by plasma exchange (PE) is more effective for patients with Guillain-Barr\u00e9 syndrome compared with IVIG alone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Retrospective chart review of 46 patients treated for Guillain-Barr\u00e9 syndrome between 1995 and 2005 was performed. Patients were divided into four subgroups based on treatment received (IVIG, PE, IVIG + PE, or neither). Disability grade on admission, after completion of IVIG, and on the day of discharge from hospital (DGD) were assessed. DGD was the primary outcome measure. Duration of hospitalization, costs, duration of symptoms before treatment, and interval between IVIG and initiation of PE were analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Mean disability grade on admission was similar for all groups. DGD was significantly lower for the IVIG group (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) than other groups. Compared with admission, patients treated with IVIG + PE had more severe impairment after completion of IVIG (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.044) but did not show significant improvement after PE. Disability grade on admission and DGD scores for patients treated earlier (less than 14 days after onset of symptoms) versus later (greater than 14 days) were not significantly different. Duration of hospitalization was longer in patients receiving IVIG + PE versus IVIG alone (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). The cost of treatment was significantly higher in the IVIG + PE subgroup (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). No correlation between interval from IVIG to PE onset and DGD score was found.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>We found no association between PE after IVIG and improved short-term outcomes of patients with Guillain-Barr\u00e9 syndrome, but there was an association with an increase in cost and duration of hospitalization. There was no association between the timing of PE after IVIG and the short-term outcome. Prospective studies are needed to clarify whether the cost\/benefit ratio favors the routine use of this therapeutic approach.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cnd.0b013e3181f3dbbf","type":"journal-article","created":{"date-parts":[[2010,11,15]],"date-time":"2010-11-15T23:49:42Z","timestamp":1289864982000},"page":"55-61","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":44,"title":["Plasma Exchange After Initial Intravenous Immunoglobulin Treatment in Guillain-Barr\u00e9 Syndrome: Critical Reassessment of Effectiveness and Cost-Efficiency"],"prefix":"10.1097","volume":"12","author":[{"given":"Malgorzata","family":"Oczko-Walker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Manousakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S","family":"Malter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Waclawik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20240808","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1056\/NEJM199204233261706","article-title":"The Guillain-Barre syndrome.","volume":"326","author":"Ropper","year":"1992","journal-title":"N Engl J Med"},{"key":"R3-1-20240808","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.35.8.1096","article-title":"Plasmapheresis and acute Guillain-Barre syndrome.","volume":"35","year":"1985","journal-title":"Neurology"},{"key":"R4-1-20240808","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group.","volume":"326","author":"Van der Meche","year":"1992","journal-title":"N Engl J Med"},{"key":"R5-1-20240808","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome.","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"R6-1-20240808","first-page":"CD001798","article-title":"Plasma exchange for Guillain-Barre syndrome.","volume":"2","author":"Raphael","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"R7-1-20240808","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/brain\/awm004","article-title":"Immunotherapy for Guillain-Barre syndrome: a systematic review.","volume":"130","author":"Hughes","year":"2007","journal-title":"Brain"},{"key":"R8-1-20240808","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0140-6736(78)92644-2","article-title":"Controlled trial of prednisolone in acute polyneuropathy.","volume":"2","author":"Hughes","year":"1978","journal-title":"Lancet"},{"key":"R9-1-20240808","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","article-title":"Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomized trial.","volume":"363","author":"Van Koningsveld","year":"2004","journal-title":"Lancet"},{"key":"R10-1-20240808","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S0140-6736(04)15962-X","article-title":"Effect of methylprednisolone in patients with Guillain-Barre syndrome.","volume":"363","author":"Susuki","year":"2004","journal-title":"Lancet"},{"key":"R11-1-20240808","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1212\/WNL.61.6.736","article-title":"Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology.","volume":"61","author":"Hughes","year":"2003","journal-title":"Neurology"},{"key":"R13-1-20240808","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(97)24050-X","article-title":"Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barre syndrome.","volume":"350","author":"Farcas","year":"1997","journal-title":"Lancet"},{"key":"R14-1-20240808","first-page":"287","article-title":"The French Cooperative Group on Plasma exchange in Guillain-Barre syndrome.","volume":"41","year":"1997","journal-title":"Ann Neurol"},{"key":"R15-1-20240808","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/jnnp.71.2.235","article-title":"Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days.","volume":"71","author":"Raphael","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R16-1-20240808","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1007\/s001340051323","article-title":"Cost analysis of plasma-exchange therapy for the treatment of Guillain-Barre syndrome.","volume":"26","author":"Esperou","year":"2000","journal-title":"Intensive Care Med"},{"key":"R17-1-20240808","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jocn.2006.03.020","article-title":"Pharmacoeconomics of therapy for Guillain-Barre syndrome: plasma-exchange and intravenous immunoglobulin.","volume":"14","author":"Tsai","year":"2007","journal-title":"J Clin Neurosci"},{"key":"R18-1-20240808","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/CND.0b013e318182b5ce","article-title":"Immunotherapy for Guillain-Barre syndrome in the US hospitals.","volume":"10","author":"Alshekhlee","year":"2008","journal-title":"J Clin Neuromuscul Dis"},{"key":"R19-1-20240808","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/jnnp.72.5.596","article-title":"Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies.","volume":"72","author":"Merkies","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R20-1-20240808","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/jnnp.2005.081547","article-title":"A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale.","volume":"77","author":"Graham","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00131402-201012000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T19:16:20Z","timestamp":1723144580000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00131402-201012000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0b013e3181f3dbbf","relation":{},"ISSN":["1522-0443"],"issn-type":[{"value":"1522-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}